Eduardo Ríos-Herranz

Eduardo Ríos-Herranz

Auto-generated profile, based on publicly available information

Eduardo Ríos-Herranz

Department of Hematology, Hospital Universitario Virgen de Valme, 41014 Sevilla, Spain

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Open access
MMMohamad Mohty
Mohamad Mohty
Evangelos TerposEvangelos Terpos
Evangelos Terpos
MMMaria-Victoria Mateos
Maria-Victoria Mateos
MCMichele Cavo
Michele Cavo
SLSandra Lejniece
Sandra Lejniece
HLHeinz Ludwig
Heinz Ludwig
The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.

27 September 2012 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
MEMonica Else
Monica Else
AMAna Marín‐Niebla
Ana Marín‐Niebla
FCFátima de la Cruz
Fátima de la Cruz
PBPaul Batty
Paul Batty
EREduardo Ríos
Eduardo Ríos
EMEstella Matutes
Estella Matutes

1 August 2020 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
HBHOSPITAL CLINIC OF BARCELONA
HOSPITAL CLINIC OF BARCELONA
CCCecilia Carpio
Cecilia Carpio
IHInmaculada Heras
Inmaculada Heras
EREduardo Ríos-Herranz
Eduardo Ríos-Herranz
JBJoan Buch
Joan Buch
Ramon Garcia-SanzRamon Garcia-Sanz
Ramon Garcia-Sanz
Clinical trials have shown that nivolumab has remarkable activity against relapsed/refractory classical Hodgkin lymphoma (cHL). However, the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) as consolidation therapy in these patients remains controversial. We performed a retrospective analysis of data from 74 patients treated with nivolumab. The overall response rate was 58% (including 30.6% with complete responses). Treatment-related adverse events were reported in 56.8% of patients (grade ≥3 in 9.4%). The main reasons for nivolumab discontinuation were referral for transplantation (41.7% patients) and disease progression (37.5%). The 2-year overall survival (OS) rate was 52% for the entire series. Ultimately, 39 patients underwent allo-HSCT. The cumulative incidence of grade II-IV acute graft-versus-host disease was 33.3% (grade III-IV in 2 patients). The cumulative incidence of nonrelapse mortality was 13.2%. Among the patients who responded to nivolumab, the 2-year OS and progression-free survival (PFS) were higher in patients who underwent consolidation with allo-HSCT (77.5% versus 42.6% [P = .126] and 73.9% versus 27.2% [P = .025], respectively). Thus, the efficacy and safety of nivolumab were comparable to values reported in previous clinical trials. The percentage of patients who bridged to transplantation was high, indicating a preference for Spanish physicians. These results suggest that consolidation allo-HSCT increases OS and PFS.

12 June 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SSSílvia Saumell
Sílvia Saumell
FSFrancesc Solé
Francesc Solé
Leonor ArenillasLeonor Arenillas
Leonor Arenillas
JMJulia Montoro
Julia Montoro
DFDavid Valcárcel Ferreiras
David Valcárcel Ferreiras
LFLourdes Florensa
Lourdes Florensa
Isolated trisomy 8 is not considered presumptive evidence of myelodysplastic syndrome (MDS) in cases without minimal morphological criteria. One reason given is that trisomy 8 (+8) can be found as a constitutional mosaicism (cT8M). We tried to clarify the incidence of cT8M in myeloid neoplasms, specifically in MDS, and the diagnostic value of isolated +8 in MDS. Twenty-two MDS and 10 other myeloid neoplasms carrying +8 were studied. Trisomy 8 was determined in peripheral blood by conventional cytogenetics (CC) and on granulocytes, CD3+ lymphocytes and oral mucosa cells by fluorescence in situ hybridization (FISH). In peripheral blood CC, +8 was seen in 4/32 patients. By FISH, only one patient with chronic myelomonocytic leukemia showed +8 in all cell samples and was interpreted as a cT8M. In our series +8 was acquired in all MDS. Probably, once discarded cT8M by FISH from CD3+ lymphocytes and non-hematological cells, +8 should be considered with enough evidence to MDS.

1 March 2011 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
AAAdrián Alegre
Adrián Alegre
BABeatriz Aguado
Beatriz Aguado
PGPilar Giraldo
Pilar Giraldo
EREduardo Ríos
Eduardo Ríos
ACAraceli Cánovas
Araceli Cánovas
JLJuan-J. Lahuerta
Juan-J. Lahuerta

21 June 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
NPNatalia Palazón-Carrión
Natalia Palazón-Carrión
AGAlejandro Martín García-Sancho
Alejandro Martín García-Sancho
ENEsteban Nogales-Fernández
Esteban Nogales-Fernández
CJCarlos Jiménez-Cortegana
Carlos Jiménez-Cortegana
FCFernando Carnicero-González
Fernando Carnicero-González
LCLuis De la Cruz-Merino
Luis De la Cruz-Merino
Purpose: New therapeutic options are needed in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide-based schedules can reverse rituximab refractoriness in lymphoma. Patients and Methods: In the phase II R2-GDP trial, 78 patients unsuitable for autologous stem cell transplant received treatment with the following schedule: lenalidomide 10 mg Days (D)1–14, rituximab 375 mg/m2 D1, cisplatin 60 mg/m2 D1, gemcitabine 750 mg/m2 D1 and D8, and dexamethasone 20 mg D1–3, up to 6 cycles (induction phase), followed by lenalidomide 10 mg (or last lenalidomide dose received) D1–21 every 28 days (maintenance phase). Primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety, and monitorization of key circulating immune biomarkers (EU Clinical Trials Register number: EudraCT 2014-001620-29). Results: After a median follow-up of 37 months, ORR was 60.2% [37.1% complete responses (CR) and 23.1% partial responses (PR)]. Median OS was 12 months (47 vs. 6 months in CR vs. no CR); median PFS was 9 months (34 vs. 5 months in CR vs. no CR). In the primary refractory population, ORR was 45.5% (21.2% CR and 24.3% PR). Most common grade 3–4 adverse events were thrombocytopenia (60.2%), neutropenia (60.2%), anemia (26.9%), infections (15.3%), and febrile neutropenia (14.1%). Complete responses were associated with a sharp decrease in circulating myeloid-derived suppressor cells and regulatory T cells. Conclusions: R2-GDP schedule is feasible and highly active in R/R DLBCL, including the primary refractory population. Immune biomarkers showed differences in responders versus progressors.